Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
9(43%)
Results Posted
0%(0 trials)
Terminated
1(5%)

Phase Distribution

Ph early_phase_1
1
5%
Ph not_applicable
5
24%
Ph phase_1
1
5%
Ph phase_2
10
48%

Phase Distribution

2

Early Stage

10

Mid Stage

0

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
1(5.9%)
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
10(58.8%)
N/ANon-phased studies
5(29.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

9

trials recruiting

Total Trials

21

all time

Status Distribution
Active(13)
Completed(2)
Terminated(1)
Other(5)

Detailed Status

Recruiting8
unknown5
Not yet recruiting4
Completed2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
9
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (5.9%)
Phase 11 (5.9%)
Phase 210 (58.8%)
N/A5 (29.4%)

Trials by Status

unknown524%
not_yet_recruiting419%
completed210%
active_not_recruiting15%
recruiting838%
terminated15%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT05412225Phase 1

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer

Recruiting
NCT07720921Phase 2

Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )

Not Yet Recruiting
NCT05479409Phase 2

Neoadjuvant Radiation in Locally Advanced Breast Cancer

Recruiting
NCT03978663Not Applicable

Three Fraction Radiation to Induce Immuno-Oncologic Response

Active Not Recruiting
NCT07254858Phase 2

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Not Yet Recruiting
NCT06924619Phase 2

Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma

Recruiting
NCT05992870Not Applicable

Neoadjuvant Radiotherapy and Immediate Implant-Based Breast Reconstruction

Recruiting
NCT06769919Phase 2

A Randomized Controlled Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined with Systemic Therapy for Early-stage Breast Cancer

Not Yet Recruiting
NCT06472752

Neoadjuvant Radiotherapy for High-risk UTUC

Not Yet Recruiting
NCT05216900Not Applicable

Breast Reconstruction and Neoadjuvant Radiotherapy

Recruiting
NCT06313073Not Applicable

Neoadjuvant Radiotherapy for Breast Cancer

Recruiting
NCT05980689Phase 2

Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer

Recruiting
NCT04489368

Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning

Unknown
NCT05507411Phase 2

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Recruiting
NCT03699410

Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.

Terminated
NCT04411537Phase 2

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSS Locally Advanced Rectal Cancer

Unknown
NCT04411524Phase 2

The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer

Unknown
NCT03520894Not Applicable

Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer

Unknown
NCT04025437Phase 2

Neoadjuvant Radiotherapy for HCC Involving Type I PVTT

Unknown
NCT03923998Early Phase 1

Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers

Completed

Drug Details

Intervention Type
RADIATION
Total Trials
21